Mezigdomide with dexamethasone and carfilzomib for treating relapsed or refractory multiple myeloma after at least 1 line of treatment [ID6513]
Awaiting development
Reference number: GID-TA11660
Expected publication date: TBC
Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin during late August 2026 when we will write to you about how you can get involved.